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Abstract
Interleukin-27 (IL-27) is a cytokine with multiple roles in regulating the immune response, but its effect on human CD56
bright
and CD56
dim NK cell subsets is unknown. NK cell subsets interact with other components of the immune system, leading to
cytotoxicity or immunoregulation depending on stimulating factors. We found that IL-27 treatment results in increased IL-
10 and IFN-c expression, increased viability and decreased proliferation in both CD56
bright and CD56
dim NK cell subsets.
More importantly, IL-27 treatment imparts regulatory activity to CD56
bright NK cells, which mediates its suppressive function
on T cells in a contact-dependent manner. There is growing evidence that CD56
bright NK cell-mediated immunoregulation
plays an important role in the control of autoimmunity. Thus, understanding the role of IL-27 in NK cell function has
important implications for treatment of autoimmune disorders.
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Introduction
In the last decade, evidence has accumulated about the possible
role of natural killer (NK) cells, a major component of the innate
immune system, in regulating the immune response by their
interaction with other components of the innate and adaptive
immunity [1] [2]. Human NK cells include two functionally and




bright NK cells, which are also known as
‘‘immunoregulatory’’, have limited cytotoxicity but secrete large
amounts of cytokines upon stimulation [3]. In contrast, CD56
dim
NK cells display higher cytotoxicity after stimulation and secrete
less cytokines [3]. CD56
bright NK cells are a small percentage (5–
10%) of the circulating NK population, whereas CD56
dim NK
cells constitute the major subset (90%) [4]. Subsets of NK cells
express different cytokine and chemokine receptors, which endow
them with different functional and homing properties [5].
Recently, the enhancement of function of CD56
bright NK cells
has been invoked as mechanism of action for the treatment of
multiple sclerosis (MS), an autoimmune with both daclizumab and
beta-interferon disease [6] [7].
IL-27 is an antigen presenting cell (APC)-derived cytokine,
having a pleiotropic effect on immune cells. For example, IL-27
promotes proliferation of naı ¨ve T cells and differentiation toward a
Th1 phenotype [8]. However, among Th1 polarized cells, IL-27
provides a feedback mechanism, triggering the secretion of the
anti-inflammatory cytokine IL-10 [9,10]. Moreover, IL-27 inhibits
Th2 and Th17 differentiation and induces IL-10 under Th17
differentiating conditions [9]. Recently, a key role for IL-27 in the
induction of IL-10 producing Tr1 cells has been reported [10,11].
Although the immunoregulatory effect of IL-27 on T cells has
been extensively studied, there are only a few reports regarding the
effects of IL-27 on total NK cell phenotype and function. It has
been reported that IL-27 induces the production of IFN-c in total
human NK cells and increases cytotoxicity in total mouse NK cells
[12,13] and that IL-27 receptor expression is down-modulated in
total mouse NK cells after activation [14] To our knowledge, there
are no studies describing the effect of IL-27 on the CD56
bright and
CD56
dim NK subsets in humans.
In this study, we investigated the effect of treating CD56
bright
and CD56
dim NK cell subsets with IL-27, on the phenotype,
proliferation, cytokine secretion and interaction of NK cells with
other cells.
Results and Discussion




IL27R is comprised of two polypeptide chains, IL-27RA
(WSX1) and gp130: of them, WSX1 is specific for IL-27, whereas
gp130 is shared by various cytokine receptor complexes [13].
Although the expression of IL-27R on activated and non-activated
NK cells has been shown previously, it was never analyzed in
different subsets of NK cells, which display remarkable differences
in phenotype, including receptors for cytokines [15]. Thus, the
expression of IL-27R on human NK cells subsets was determined
by real time PCR and by FACS analysis of surface expression of
WSX1 specific subunit on both NK subsets. We found that both
subsets express mRNA for IL27R (figure 1a) and express the
protein on the surface with an increased expression on surface of
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bright compared to CD56
dim subset (p,0.05, figure 1b and
figure 1c) as shown by FACS analysis.
IL-27 increases expression of IL-10 and IFN-c and
decreases proliferation in CD56
bright and CD56
dim NK
cells. Viability of NK cell subsets is increases by IL-27
An important way by which NK cells, and especially the
CD56
bright subset, influence innate and adaptive immune
responses is the secretion of cytokines, among them IFN-c is the
most prominent, and under certain conditions, IL-10 is secreted
[16] [3]. We asked whether the reported effect of IL-27 on IFN-c
secretion by NK cells occurred in both subsets, and whether IL-27
could also induce IL-10 secretion in NK cell subsets, given that this
is observed following IL-27 stimulation of CD4+ T cells. We
measured the expression of IFN-c and IL-10 by real-time PCR.
Although we did not observe induction of these cytokines when we
stimulated NK cells with IL-27 alone (figure 2a and figure 2b) we
observed increased expression of both IL-10 and IFN-c in
CD56
bright and CD56
dim NK cells stimulated with IL-12 and IL-
15 and treated with IL-27 (figure 2a and 2b). It is known that IL-
12 and IL-15 induce the secretion of both cytokines in NK cells
[3]. The induction of a ‘‘pro-inflammatory’’ cytokine, such as IFN-
c, and of the immunosuppressive cytokine IL-10, may appear
contradictory. However, it has been shown that in NK cells, IL-10
secretion may occur in association with IFN-c and that IL-
10
+IFN-c
+ NK cells have immunosuppressive properties e.g.,
suppressing the secretion of the pro-inflammatory cytokine IL-12
by dendritic cells [17]. Of note regulatory Tr1 cells, induced by IL-
27, also produce both IL-10 and IFN-c [10].
We then investigated the influence of IL-27 on proliferation and
viability of human NK cells [18,19]. IL-27 alone did not induce
proliferation of NK cells. We observed that IL-27 decreased IL-12
and IL-15 induced proliferation in both NK subsets (figure 2c). To
exclude the possibility that this resulted from increased cell death
in IL-27 stimulated NK cells, we measured viability of NK cells
after the culture. We did not find decreased viability of NK cells
stimulated with IL-27, IL-12 and IL-15 compared to IL-12 and
IL-15 (mean viability: 55.2620.8% and 48.3623.5 in the two
groups, figure 2d). While many cytokines have been reported to
enhance proliferation of NK cells alone or in synergy with other
stimuli [20], we describe for the first time that a cytokine, IL-27,
has an anti-proliferative effect on NK cells. A similar anti-
proliferative effect of IL-27 on activated T cells was reported
previously and is thought to be critical in preventing destructive
inflammation during systemic infections [21]. We also measured
the influence of IL-27 alone on NK cell viability, by culturing both
NK cell populations in the presence or absence of IL-27 for
72 hours. We found that NK cell viability was significantly
enhanced in both NK subsets in the presence of IL-27 with no
differences between CD56
bright vs. CD56
dim NK cells (figure 2d).
These results demonstrate enhancement of NK cell survival in the
presence of IL-27 and are consistent with reports showing that
mouse NK cells, cultured in the presence of IL-27, have an
increased viability [13].




Cytotoxicity is an important function of CD56
dim NK cells [22].
Resting CD56
dim NK cells are poorly cytotoxic, while activation
with cytokines such as IL-2, IL-12, IL-15 and IL-21 enhances their
cytotoxic features [20]. Thus, we tested IL-27-stimulated CD56
dim
NK cells in a cytotoxic assay using K562 cells and measured both
the percentage of dead cells and the percentage of degranulated
(CD107a positive) CD56
dim NK cells as a marker for cytotoxicity.
IL-27 stimulation did not enhance cytotoxicity by CD56
dim NK
cells or influenced the degranulation as measured by CD107a
expression (figure 3a and 3b).
We then evaluated the effect of IL-27 on NK cells effector
functions and on their interactions with target cells. Since IL-27 is
able to induce CD4+T cells with regulatory functions [10] [11], we
Figure 1. NK cells express IL-27 receptor. (a) Expression of WSX-1, subunit of IL-27R, as measured by real-time PCR in purified the CD56
bright and
CD56
dim NK cells. Mean 6 standard deviation of a representative experiment (of three independent experiments) is shown. (b) Expression of IL-27
receptor subunit WSX-1 on the surface of purified CD56
bright and CD56
dim NK cells, as measured by the FACS. One representative experiment of eight
experiments. (c) FACS histogram showing expression of IL-27R (red profiles) on CD56
bright and (d) on CD56
dim NK cells compared to isotype control
(filled grey profiles).
doi:10.1371/journal.pone.0026173.g001
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NK cells. Thus, we cultured viable IL-27-treated or control
CD56
bright or CD56
dim NK cells with autologous CD4+ T cells
stimulated with beads coated with anti-CD3 and anti-CD28. We
found that IL-27 treated CD56
bright NK cells demonstrated
increased suppression of autologous CD4+T cells proliferation
compared to untreated CD56
bright NK cells (figure 3c). As
expected, we did not observe suppression by CD56
dim NK cells
in the presence or absence of IL-27 (data not shown). To
determine the mechanism involved in suppression mediated by IL-
Figure 3. IL-27 does not induce cytotoxicity in CD56
dim NK cells, but imparts immunoregulatory function to CD56
bright NK cells.
Degranulation (a) and cytotoxicity (b) of CD56
dim NK cells after stimulation with or without IL-27. Purified CD56
dim NKcells were cultured for 72 hours
in the presence or absence of IL-27. Viable cells were re-sorted and cultured with or without the target cell line K562 for 4 hours or were stained for
CD107a. One representative experiment is shown of 5–7 experiments. (c) Suppression assay of CD56
bright NK cells activated for 72 hours with IL-27.
Live cells were sorted and cultured with autologous purified CD4+ T cells in the presence of anti-CD3 and anti-CD28 coated beads. Cell proliferation
was assessed after five days as shown with mean+s.d. in triplicate wells, one of seven experiments is shown. (d) Suppressive activity of NK cells
activated in the presence of IL-27 and incubated in contact with responder T cells (Control) or with a transwell (Transwell). (e) Expression of molecules
involved in NK cell mediated cytotoxicity in CD56
bright NK cells treated with IL-27 after 72 hours.
doi:10.1371/journal.pone.0026173.g003
Figure 2. IL-27 induces the expression of IL-10 and IFN-c in CD56bright and CD56dim NK cells. IL-27 decreases the proliferation of NK
cells subsets and enhances their survival. (a) and (b) Expression of IL-10 and IFN-c as measured by real-time PCR. Purified CD56
bright and CD56
dim NK
cells were cultured for 24 hours in medium only, in presence of IL-27 only or in presence IL-12 plus IL-15 with or without IL-27. (c) Proliferation of
CD56
bright and CD56
dim NK cells after culture in medium only, with IL-27 only and with IL-12 plus IL-15 with or without IL-27. Cell proliferation is
shown as mean c.p.m.+s.d. in triplicate wells. (d) Viability of CD56
bright and CD56
dim NK cells as determined by the FACS after 72 hours of culture in
the presence of the IL-27 compared to no stimulus, and in the presence of IL-12 plus IL-15 with or without IL-27. Dead cells were selected as AAD-
positive cells. One experiment of 5–10 independent experiments is shown in each panel.
doi:10.1371/journal.pone.0026173.g002
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bright NK cells, co-cultures were performed in a
transwell system. We found that suppression mediated by IL-27
treated NK cells was completely abolished in the transwell,
suggesting that contact dependent mechanisms are required for
CD56
bright NK cells to exert suppression (figure 3d). As NK cell
cytotoxicity is primarily dependent upon cytotoxic enzymes such
as perforin and granzyme B we sought to dissect which factors are
involved in the suppression mediated by IL-27-treated CD56
bright
NK cells [23]. We performed a gene expression profile of treated
and untreated NK cells for molecules involved in cytotoxicity in
NK cells. We observed a selective increase in the expression of
perforin in IL-27-treated CD56
bright NK cells compared to
untreated CD56
bright NK cells (figure 3e). This observation,
together with the requirement of cell contact, might suggest a
cytotoxic action of IL-27 stimulated CD56
bright NK cells on
activated T cells; however, a direct link between perforin gene
transcription induction and T cells proliferation suppression
cannot be proven and should be the subject of further studies,
In summary our study shows a new immunoregulatory feature
of IL-27 on important components of the innate immune system,
the CD56
bright and CD56
dim NK cell subsets. There is growing
evidence that NK cells, and particularly the CD56
bright subset, can
affect the adaptive immune response through the secretion of
cytokines and through a contact-dependent suppression of
lymphocyte proliferation. This is of particular importance, as an
increase in CD56
bright NK cell-mediated suppression of T cells is
the presumed mechanism by which anti-CD25 monoclonal
antibody (daclizumab) exerts its beneficial effects in multiple
sclerosis [6] [24]. However, the mechanisms that induce these
positive effects are not understood, and whether resting CD56
bright
cells exert such effects, is not known. Here we show that treatment
with IL-27 is able to induce suppressive function in CD56
bright NK
cells and to increase the expression of IL-10, without affecting the
natural cytotoxicity of CD56
dim NK cells towards common targets.
Thus treatments which enhance IL-27 would be expected to
enhance the immunoregulatory function of NK cells and could be




Peripheral blood leukopak cells were obtained from Children’s
Hospital, Boston MA. The leukopak cells are obtained at the time
of routine blood donation in which subjects provide written
consent to have blood drawn. These procedures are in accordance
with the Children’s Hospital Institutional Review Board. The
human cells are analyzed in our laboratory at the Brigham and
Women’s Hospital. Our laboratory is approved by the institutional
review board at Brigham and Women’s hospital for the study of
human blood.
Cell culture media, antibodies and reagents
RPMI 1640 was supplemented with 5% heat-inactivate human
serum (HS), 1% nonessential amino acids, 1% sodium pyruvate,
1% HEPES buffer, 1% L- Glutamine and 1% penicillin and
streptomycin (Gibco, Life technologies, Carlsbad California USA).
Antibodies to CD3, CD28, IL-10, IFN-c, CD69, CD56 and CD16
and dead cell indicator AAD were obtained from BD Biosciences.
All RT-PCR primers and reagents were obtained from Applied
Biosystems Life Technologies, Carlsbad California, USA. Recom-
binant human IL-27, IL-12 and IL-15 were obtained from R&D
systems, Minneapolis, USA.
Purification of human NK cell subsets
PBMCs were obtained by Ficoll density gradient. Total NK
cells were negatively purified using a Miltenyi Biotech negative
selection kit. CD3-CD56
bright and CD3-CD56
dim NK cells were




bright NK and CD56
dim NK cells were cultured at a
concentration of 2610
5 cells/well in 96-well cell round-bottom
culture plates in presence or absence of IL-27 (50 ng/ml) alone or
in combination with IL-12 (10 ng/ml) and IL-15 (100 ng/ml).
Cells were harvested 24 hours later for RNA extraction. Cell free
culture supernatants were collected for cytokine analysis either by
ELISA or BD cytometric bead array after 72 hours. Cells were
analyzed for phenotypic markers by flow cytometry and for
functional assays after 72 hours.
Proliferation assays
Cell cultures were pulsed after 72 h of culture with
[3H]thymi-
dine at 1 mCi/well for the final 18 h, harvested, and assayed for
proliferation. Mean incorporation of thymidine was measured in
triplicate wells and is indicated as counts per minute (cpm).
Quantitation by real-time PCR
Total RNA was isolated from cell pellets using RNAeasy Mini
Kit (Qiagen). First-strand cDNA synthesis was performed for each
RNA sample from 0.5–1 mg of total RNA using Taqman reverse-
transcription reagents. cDNA was amplified using sequence-
specific primer and real-time PCR mix (Applied Biosystems) on
ABI 7500 cycler. GAPDH gene was used as an endogenous
control to normalize total RNA in each sample. All values were
expressed as relative expression of gene of interest to the
expression of GAPDH.
CD107a assay and cytotoxicity assay
CD56
dim NK cells cultured with or without IL-27 were
harvested after 72 hours, stained with 7-amino-actinomycin D
(7-AAD, BD Biosciences) and sorted viable cells as 7-AAD
negative cells. Viable cells were then co-cultured with or without
a target cell line (K562, ATCC) at an effector-target ratio of 10:1
for 4 hours. Half of the cells were cultured in presence of CD107a
antibody (8 ul/well) or isotype control. Brefeldin A (Golgi plug,
BD Bioscences) was added after an hour of culture at 0.8 ul/well.
After 4 hours of culture, cells were harvested, stained with CD56
and immediately read with an LSR II flow cytometry. Half of the
cells were cultured in absence of CD107a and brefeldin A and
were stained, at the end of the culture, with anti-CD56 and 7-
AAD, and then immediately read by flow cytometry (LSR II, BD
Biosciences, CA, USA). Percentage of CD107a+ CD56+ and
CD107a-CD56+ cells as well as percentage of CD56-
CFSE+7AAD+ (dead target cells) and CD56-CSFE+7AAD2 cells
(alive target cells) were evaluated.
Suppression assay
After 72 hrs of culture, CD56
bright NK cells cultured with or
without IL-27 were harvested and sorted for live (7-AAD negative)
cells. CD4+ T cells negatively isolated (Miltenyi kit) from the same
individual were cryopreserved in DMSO. 5000 CD4+ T cells were
activated with 2500 anti-CD3 and anti-CD28 beads (Dynal beads
obtained from Invitrogen, Life Technologies, Carlsbad, USA) for
5 days in the presence of 5000 CD56
bright/dim cells previously
cultured with or without IL-27. CD4+ T cells alone and
Immunoregulatory Function of IL-27 on NK Cells
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bright/dim cells alone were used as controls. Cells were pulsed
with
3H-thymidine (1 mCi/well) for 16–24 hrs at the end of the
incubation period.
Statistical analysis
The following statistic tests were used: two-tailed paired t-test,
two tailed Wilcoxon matched-pairs test, Kruskal-Wallis test with
Dunn’s multiple comparisons test. A p#0.05 was considered
significant.
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